Dr. Chao graduated with honors from the University of California, Los Angeles with a B.S. in Microbiology and Molecular Genetics and received her M.D. from University of California, Irvine. As a Howard Hughes Scholar at the National Human Genome Research Institute (NHGRI), Dr. Chao specialized in genomic technologies and cancer genetics. More recently her research has focused on novel methods for interpreting DNA variants. Dr. Chao completed her training in Clinical Molecular Genetics at the Children’s Hospital of Philadelphia (CHOP) and prior to joining Ambry, served as Associate Director of the Genetic Diagnostic Lab at the University of Pennsylvania. 

Dr. Li received a B.S. in Microbiology from Nankai University, and a Ph.D. in Bioinformatics from University of Illinois at Chicago. He did his post-doctoral training on biological network and Systems Biology in the Department of Bioengineering at the University of California, San Diego (UCSD). He has more than 10 years of experience and numerous publications in the machine learning and AI. Dr. Li's Ph.D. work used computational biophysics and supervised (machine) learning algorithm to distinguish native protein structures from non-native structures. Recently, his research has focused on the classification of functional variants versus non-functional variants in personal genomes. Dr. Li led a bioinformatics team helping Ambry Genetics launch the Clinical Diagnostic Exome™ sequencing, which marked the first time the exome sequencing had been made available on a clinical basis. He is now leading the Bioinformatics Department of Ambry Genetics to develop ground-breaking bioinformatics infrastructure and pipelines, which are transforming the landscape of the clinical genetics industry in the post-genomic era. 

Gretchen Enright received her undergraduate degree in Biology and Chemistry at Moravian College in Bethlehem, PA, completed medical technology training and received her Master’s degree in Business Administration from Webster University in Irvine, CA. Gretchen is licensed by ASCP and CA state in Molecular Biology and has 17 years of experience in independent reference laboratories. She most recently worked at Clarient Diagnostics, Inc. a GE Healthcare company where she held Director of Compliance, regulatory affairs and QA roles. Gretchen’s experience has been in somatic and germinal genetic disease testing and regulatory oversight of such testing, as well as regulatory and quality oversight of Pharmaceutical study testing for therapeutic development and targeting. Gretchen initially received her training on the CAS 200 for quantifying DNA in tumor cells at Sacred Heart Hospital in Allentown, PA during her medical technology training, after which she transferred this technology to Nichols Institute (now Quest Diagnostics). She further evolved from immunohistochemistry techniques to molecular pathology and DNA/RNA analysis.